Pancreatic Cancer Treatment Outcomes Lack Distributed Intelligence

Pancreatic cancer has a dismal 5-year survival rate of 12%, largely due to the inability to share treatment outcome data across institutions. This article discusses how the heterogeneity of the disease and the lack of a 'routing layer' for outcome intelligence prevents effective knowledge sharing and clinical trial matching.

Details

Pancreatic cancer has one of the worst survival rates among major cancers, with a 5-year survival of only 12%. The article argues that the primary issue is not the biology of the disease, but rather the lack of an effective 'architecture' for sharing treatment outcome intelligence across institutions. Pancreatic cancer is highly heterogeneous, with distinct molecular subtypes that respond differently to various therapies. However, the small number of patients per subtype at individual treatment centers means there is insufficient local data to power federated learning approaches. The outcome data that does exist is largely siloed within each institution, preventing the accumulation of subtype-specific intelligence that could guide better treatment decisions. The article also highlights the challenge of manually matching patients to relevant clinical trials, a labor-intensive process that relies on distributed outcome data that is not easily accessible. Current retrospective data sources like tumor registries provide historical information, but do not enable real-time synthesis of the latest treatment outcomes. The article suggests that a distributed intelligence routing protocol like QIS could help address these challenges by facilitating the exchange of outcome packets without requiring centralization of patient data.